

**Your reference**  
**Our reference**  
**Date**

October 9, 2023

**Changes to abrdn SICAV I - All China Sustainable Equity Fund (the “Underlying Fund”)**

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

We accept full responsibility for the accuracy of the content of this document.

Dear valued customer,

We are writing to let you know about the changes to the Underlying Fund. You have invested in at least one of the investment choices corresponding to the Underlying Fund, which are listed in the “Which investment choices are affected?” table below under the column “Name and code of the investment choice”.

**Which investment choices are affected?**

<b>Name and code of the investment choice (Individually, the “Investment Choice”; collectively, “Investment Choices”)</b>	<b>Name of the corresponding Underlying Fund</b>	<b>Applicable scheme (the “Schemes”)</b>
abrdn SICAV I - All China Sustainable Equity Fund (Code: OIUSD)	abrdn SICAV I - All China Sustainable Equity Fund	<ul style="list-style-type: none"> <li>• International Wealth Account</li> <li>• IWA</li> <li>• Pacific</li> </ul>
ZI abrdn SICAV I All China Sustainable Equity Fund (Code: ASUSD)		<ul style="list-style-type: none"> <li>• Futura II</li> <li>• Futura III</li> <li>• Elite International Bond</li> <li>• SUPRA Savings and Investment Plan</li> <li>• Vista</li> <li>• Vista Retirement Scheme</li> </ul>

**Zurich International Life Limited**  
(a company incorporated in the Isle of Man with limited liability)

25-26/F, One Island East  
18 Westlands Road  
Island East, Hong Kong

Website: [www.zurich.com.hk](http://www.zurich.com.hk)

Zurich International Life Limited provides life assurance, investment and protection products and is authorized by the Isle of Man Financial Services Authority.

Registered in the Isle of Man number 20126C.

Registered office: Zurich House,  
Isle of Man Business Park,  
Douglas, Isle of Man, IM2 2QZ,  
British Isles

### **What is happening?**

We have been notified by abrdn SICAV I of the decision of the board of directors of abrdn SICAV I (the “**Board of Directors**”) to merge abrdn SICAV II - China Equities Fund, a sub-fund of abrdn SICAV II (the “**Merging Fund**”), by way of merger by absorption, into the Underlying Fund (the “**Merger**”) on Friday November 24, 2023 (the “**Effective Date**”).

The Merger will be effected in accordance with the provisions of article 1(20) a) and with Chapter 8 of the Luxembourg law of December 17, 2010 relating to undertakings for collective investment, as amended. The Merger complies with the provisions of article 20(ii) of the articles of incorporation of abrdn SICAV I.

### **Background to and rationale for the Merger**

The Merger is part of a rationalisation of abrdn’s Luxembourg fund range. The aim of the rationalisation is to ensure they have an appropriate fund range which can operate at optimal efficiency to generate value and return on investments investors. The aim is also to generate efficiencies in the management and marketing of products. The rationalisation includes consolidation of investment vehicles, as well as merging funds that pursue similar investment strategies. They believe that implementation of the Merger is in the best interests of the investors.

### **Impact on the Underlying Fund**

The Underlying Fund’s investment portfolio will not need to be rebalanced before or after the Merger, however rebalancing of the Merging Fund’s portfolio will be required prior to the Merger. Any costs arising as a result of such rebalancing of the Merging Fund shall be borne by the investors of the Merging Fund.

The Underlying Fund will continue to be managed according to its current investment objective and policy after the Merger.

Consequently, the Board of Directors does not anticipate any material impact on the Underlying Fund’s investment portfolio or performance as a result of the Merger.

### **Impact on the dealing and valuation times**

In order to facilitate the Merger and minimise the risk of an operational error which may arise due to the Merger, the Board of Directors, in accordance with Article 21 of the articles of incorporation of abrdn SICAV I and in consultation with Citibank Europe plc, Luxembourg branch, the Depositary of the Underlying Fund, has decided to suspend calculation of the net asset value and thus dealing in the shares of the Underlying Fund on the Effective Date, November 24, 2023. The Board of Directors believes that such a suspension is in the best interests of investors of the Underlying Fund.

### **Expenses and costs**

There will be no cost impact on the Underlying Fund resulting from the Merger. All other costs of implementing the Merger, including legal, accounting and other administrative expenses, as well as portfolio transfer costs (including stamp duty, transfer taxes and other similar duties) will be paid by abrdn plc or another entity in the abrdn plc group.

In relation to the Underlying Fund, copies of the existing prospectus, the Hong Kong supplement and product key fact statement (“**KFS**”) of the Underlying Fund will be made available at [www.abrdn.com/hk](http://www.abrdn.com/hk)<sup>1</sup>.

---

<sup>1</sup> Please note that the website has not been reviewed by the Securities and Futures Commission.

**What does this mean to you?**

If you wish to continue to invest in the Investment Choice(s) after considering the changes outlined above, you will not need to take any action. However, if you do not wish to maintain your investment in the Investment Choice(s), you may switch your existing holdings or redirect your future contribution allocations to alternative investment choice(s) by submitting an instruction to us, free of charge.

We recommend that you contact your licensed insurance intermediary in the first instance, who will be able to advise you of the alternative investment choice(s). For information on the fees and charges and the respective risk factors of our range of investment choices, please refer to the product brochure of the respective Schemes and the offering documents of the underlying funds made available by us upon request.

If you have any questions about this letter or your investment in the investment choice(s), please contact your licensed insurance intermediary, or you can call our customer care hotline at +852 3405 7150 or email us at [helppoint.hk@hk.zurich.com](mailto:helppoint.hk@hk.zurich.com) and we will be happy to help.

Yours faithfully,

Zurich International Life Limited  
(a company incorporated in the Isle of Man with limited liability)

***Note: Please note investments involve risks. The value of any investment and the income from it can fall as a result of market and currency fluctuations and you could get back less than the amount originally invested.***

### 有關安本基金 - 全方位中國可持續股票基金 (「該相關基金」) 之變更

蘇黎世國際人壽保險有限公司  
(於人島註冊成立之有限公司)

香港港島東華蘭路18號  
港島東中心25-26樓

網址：www.zurich.com.hk

蘇黎世國際人壽保險有限公司是人島  
Financial Services Authority所認可，  
提供人壽保險、投資及保障產品。

於人島的註冊號碼為20126C。

註冊辦事處：Zurich House,  
Isle of Man Business Park,  
Douglas, Isle of Man, IM2 2QZ,  
British Isles

此乃重要函件，務請您即時垂注。您如對本函件的內容有任何疑問，請尋求專業意見。

我們就此函件所轉載資料的準確性承擔全部責任。

親愛的客戶：

我們謹此致函通知您有關該相關基金的變更。您已投資於該相關基金相應的至少一個投資選擇，其列於下表「受影響的投資選擇」中「投資選擇的名稱及代碼」一欄。

#### 受影響的投資選擇

投資選擇 (各稱為「該投資選擇」，統稱為「該等投資選擇」) 的名稱及代碼	相應的該相關基金名稱	適用計劃 (「計劃」)
安本基金 - 全方位中國可持續股票基金 (代碼：OIUSD)	安本基金 - 全方位中國可持續股票基金	<ul style="list-style-type: none"> <li>國際創富計劃</li> <li>景緻人生</li> <li>翱翔人生</li> </ul>
蘇黎世國際安本全方位中國可持續股票基金 (代碼：ASUSD)		<ul style="list-style-type: none"> <li>「樂安閑」計劃</li> <li>「樂安閑」III</li> <li>卓越精英國際投資計劃</li> <li>至尊國際儲蓄投資</li> <li>豐盛人生</li> <li>豐盛人生退休計劃</li> </ul>

#### 修訂事項

安本基金已通知我們關於安本基金董事會 (「董事會」) 以吸收合併的方式將安本基金II的附屬基金安本基金II - 中國股票基金 (「被合併基金」) 併入該相關基金 (「合併」) 的決定，生效日期為2023年11月24日星期五 (「生效日期」)。

合併將按照2010年12月17日關於集體投資計劃的盧森堡法律 (經修訂) 第1(20) a)條及第8章的規定執行。合併符合安本基金組織章程第20(ii)條的規定。

#### 合併的背景和理由

本次合併為安本盧森堡基金系列理順的一部分。理順的目標是確保安本基金擁有能夠以最佳效率運作的適當基金系列，從而為投資者創造價值及投資回報。目標亦包括提升產品管理及推廣的效率。理順內容包括整合投資工具，以及合併奉行相似投資策略的基金。安本基金認為實施合併符合投資者的最佳利益。

#### 對該相關基金的影響

該相關基金的投資組合在合併前或合併後將無需重新調整，但被合併基金的投資組合在合併前將需要重新調整。由於被合併基金重新調整引起的任何成本須由被合併基金的投資者承擔。

在合併後，該相關基金將繼續按照其當前的投資目標及政策進行管理。

因此，董事會預計合併不會對該相關基金的投資組合或表現產生任何重大影響。

### 對交易和估值時間的影響

為推進合併以及盡量降低合併可能引起的運作錯誤風險，董事會根據安本基金組織章程第21條並經與該相關基金存管人Citibank Europe plc, Luxembourg branch協商後，已決定於2023年11月24日，即生效日期暫停計算該相關基金的資產淨值及暫停進行股份交易。董事會認為暫停一事符合該相關基金投資者的最佳利益。

### 開支和成本

合併不會對該相關基金產生成本影響。實施合併的所有其他成本，包括法律、會計及其他行政開支，以及投資組合轉讓成本（包括印花稅、轉讓稅及其他相似稅費）將由abrdn plc或abrdn plc集團內的另一家實體支付。

就該相關基金而言，其現有招股說明書、香港補充文件和產品資料概要（「KFS」）可在網站[www.abrdn.com/hk](http://www.abrdn.com/hk)<sup>1</sup>免費查閱。

### 對您產生的影響

如您在考慮上述變更後仍繼續投資於該等投資選擇，則無需就此修訂作出任何行動。倘若您不欲繼續投資於該等投資選擇，可向本公司遞交轉換現有投資或重新指定未來供款分配至其他投資選擇的指示，費用全免。

我們建議您首先諮詢您的持牌保險中介人，以取得其他投資選擇的建議。有關本公司投資選擇（包括費用及收費，以及其相關風險因素）的詳情，請參閱相關計劃的產品介紹冊及相關基金的銷售文件，本公司會應要求提供上述銷售文件。

如您對本函件或投資選擇中的投資有任何問題，請聯絡您的持牌保險中介人。您亦可致電+852 3405 7150或電郵至[helppoint.hk@hk.zurich.com](mailto:helppoint.hk@hk.zurich.com)聯絡客戶服務部，我們將樂意為您效勞。

蘇黎世國際人壽保險有限公司  
（於人島註冊成立之有限公司）  
2023年10月9日

**註：投資涉及風險，您的投資價值及收益可因市場及貨幣波動而下跌，有可能導致您不能取回所有投資款項。**

---

<sup>1</sup> 請注意，該網站未經證監會審閱。